Claritas Genomics appoints Patrick Terry as chief commercial officer

18 December 2014

Genetic diagnostic lab, Claritas Genomics, has appointed Patrick Terry as chief commercial officer.

He is chairman of Gray Group Ventures and a founder of Genomic Health (Nasdaq: GHDX) and has experience of guiding several biotech products through commercial development to clinical delivery.

He has co-founded and advised multiple life science ventures, and been part of securing more than $600 million in financing. After founding PXE International, Terry was a Principal with Scientia Advisors Inc. and co-founded the Personalized Medicine Coalition, European Personalized Medicine Association, and the International Genetic Alliance, He has held numerous national and international leadership positions and has published extensively in the fields of genetics, personalized medicine, and biomedical research.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology